News Hub

Mayo Clinic partners with SimBioSys for AI-driven breast cancer medicine

Written by Thu 4 Jan 2024

The academic medical centre, Mayo Clinic, and TechBio company, SimBioSys, have partnered for the development of AI-driven digital precision medicine solutions for breast cancer patients.

The collaboration aims to use AI to develop cloud-based clinical software tools that will support the end-to-end decision-making process for early-stage breast cancer patients. This will include individualised surgical planning, treatment, drug selection, and risk stratification.

The rapidly changing landscape in breast cancer spurred the collaboration.

Mayo Clinic and SimBioSys said there is an urgent need to individualise care and identify opportunities where both surgical and medical treatments can be safely right-sized to improve quality of life without compromising on outcomes.

“In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care … SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging,” said Tushar Pandey, Co-founder and CEO of SimBioSys. 

As part of the collaboration, SimBioSys was given access to and has been analysing data from patients who participated in the Mayo Clinic-led BEAUTY clinical trial

SimBioSys uses AI and data science to reveal spatial biophysical insights that will help clinicians better tailor treatment plans for each patient.

SimBioSys will conduct simulations using pre-existing data. In addition to validating the predictive accuracy of the platform, the team will engage in in-silico scenario analysis under the guidance of the Mayo Clinic team.

The team is actively working on the development of TumorSight, a cloud-based platform designed as a medical device. This platform will be utilised in clinical settings for the treatment planning process. 

The company’s first product on the TumorSight platform takes a patient’s standard of care DCE-MRI imaging to build a custom 3D digital model of their tumour. This product is currently under FDA review. 

TumorSight provides surgical oncologists with 3D spatial visualisations of breast cancer to support more effective surgical planning and patient consultations. Clear 3D ‘digital twin’ renderings instantly display the tumour in the context of auto-segmented anatomical structures like skin, vessels, the chest, fat, glands, and the heart.

The SimBioSys clinical advisory team is supported by Mayo Clinic physicians Judy C. Boughey, M.D. and Matthew Goetz, M.D.

Mayo Clinic has been designated a Comprehensive Cancer Centre by the National Cancer Institute and is one of only 45 NCI-designated comprehensive centres in the US. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

Join Big Data & AI World

6-7 March 2024, ExCeL London

Be at the forefront of change with thousands of technologists, data specialists, and AI pioneers.

Don’t miss the biggest opportunities to advance your business into the future.

Written by Thu 4 Jan 2024

Send us a correction Send us a news tip